Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells $153,628.44 in Stock

Soleno Therapeutics, Inc. (NASDAQ:SLNO) insider Kristen Yen sold 3,108 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $49.43, for a total transaction of $153,628.44. Following the completion of the transaction, the insider now owns 81,465 shares of the company’s stock, valued at $4,026,814.95. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kristen Yen also recently made the following trade(s):

• On Wednesday, August 28th, Kristen Yen sold 5,270 shares of Soleno Therapeutics stock. The stock was sold at an average price of $47.58, for a total transaction of $250,746.60.
• On Monday, August 5th, Kristen Yen sold 5,017 shares of Soleno Therapeutics stock. The shares were sold at an average price of $45.77, for a total transaction of $229,628.09.

Soleno Therapeutics Trading Up 1.4 %

Shares of SLNO stock opened at $49.63 on Friday. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of -18.52 and a beta of -1.45. The firm has a 50-day moving average price of $48.87 and a 200 day moving average price of $45.09. Soleno Therapeutics, Inc. has a twelve month low of $21.30 and a twelve month high of $55.56.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.06. As a group, research analysts predict that Soleno Therapeutics, Inc. will post -2.28 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Amalgamated Bank purchased a new stake in shares of Soleno Therapeutics in the second quarter valued at $31,000. Victory Capital Management Inc. grew its holdings in Soleno Therapeutics by 26.3% in the 2nd quarter. Victory Capital Management Inc. now owns 10,727 shares of the company’s stock valued at $438,000 after buying an additional 2,236 shares during the period. Cannon Global Investment Management LLC acquired a new position in shares of Soleno Therapeutics during the 1st quarter valued at about $505,000. Sei Investments Co. lifted its holdings in shares of Soleno Therapeutics by 22.0% during the 1st quarter. Sei Investments Co. now owns 12,577 shares of the company’s stock worth $538,000 after acquiring an additional 2,264 shares during the period. Finally, California State Teachers Retirement System boosted its position in shares of Soleno Therapeutics by 33.8% in the first quarter. California State Teachers Retirement System now owns 13,780 shares of the company’s stock worth $590,000 after acquiring an additional 3,481 shares during the last quarter. 97.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

SLNO has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price objective on shares of Soleno Therapeutics in a research note on Friday, September 20th. HC Wainwright initiated coverage on Soleno Therapeutics in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $70.00 price target for the company. Oppenheimer boosted their price objective on shares of Soleno Therapeutics from $59.00 to $65.00 and gave the stock an “outperform” rating in a research report on Monday, August 12th. Finally, Stifel Nicolaus raised their target price on shares of Soleno Therapeutics from $59.00 to $74.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $68.71.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.